WO2001029085A3 - Cdt6 can inhibit angiogenesis and tumor growth, and can induce or enhance the formation of structures containing collagen v - Google Patents

Cdt6 can inhibit angiogenesis and tumor growth, and can induce or enhance the formation of structures containing collagen v Download PDF

Info

Publication number
WO2001029085A3
WO2001029085A3 PCT/NL2000/000674 NL0000674W WO0129085A3 WO 2001029085 A3 WO2001029085 A3 WO 2001029085A3 NL 0000674 W NL0000674 W NL 0000674W WO 0129085 A3 WO0129085 A3 WO 0129085A3
Authority
WO
WIPO (PCT)
Prior art keywords
cdt6
tumor growth
induce
enhance
formation
Prior art date
Application number
PCT/NL2000/000674
Other languages
French (fr)
Other versions
WO2001029085A2 (en
Inventor
Ronald Peek
Original Assignee
Royal Netherlands Academy Of A
Ronald Peek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Royal Netherlands Academy Of A, Ronald Peek filed Critical Royal Netherlands Academy Of A
Priority to AU13102/01A priority Critical patent/AU1310201A/en
Publication of WO2001029085A2 publication Critical patent/WO2001029085A2/en
Publication of WO2001029085A3 publication Critical patent/WO2001029085A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

In spite of the classification of CDT6 as a nonangiopoietin member of the fibrinogen domain containing superfamily, we have demonstrated that CDT6 has a potent effect on angiogenesis and tumor growth. CDT6 is capable of inhibiting at least in part angiogenesis. The invention provides the use of this novel angiogenesis antagonist in the treatment of diseases, preferably cancers that form solid tumors.
PCT/NL2000/000674 1999-10-21 2000-10-19 Cdt6 can inhibit angiogenesis and tumor growth, and can induce or enhance the formation of structures containing collagen v WO2001029085A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU13102/01A AU1310201A (en) 1999-10-21 2000-10-19 Cdt6 can inhibit angiogenesis and tumor growth, and can induce or enhance the formation of structures containing collagen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99203466 1999-10-21
EP99203466.0 1999-10-21

Publications (2)

Publication Number Publication Date
WO2001029085A2 WO2001029085A2 (en) 2001-04-26
WO2001029085A3 true WO2001029085A3 (en) 2002-01-31

Family

ID=8240767

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2000/000674 WO2001029085A2 (en) 1999-10-21 2000-10-19 Cdt6 can inhibit angiogenesis and tumor growth, and can induce or enhance the formation of structures containing collagen v

Country Status (2)

Country Link
AU (1) AU1310201A (en)
WO (1) WO2001029085A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10435444B2 (en) 2015-04-17 2019-10-08 The University Of Tokyo Agent for prevention or treatement of corneal disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015653A2 (en) * 1997-09-19 1999-04-01 Genentech, Inc. Tie ligand homologues
WO1999032639A1 (en) * 1997-12-19 1999-07-01 Regeneron Pharmaceuticals, Inc. Receptor tyrosine kinase, ar-1, is a regulator of angiogenesis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015653A2 (en) * 1997-09-19 1999-04-01 Genentech, Inc. Tie ligand homologues
WO1999032639A1 (en) * 1997-12-19 1999-07-01 Regeneron Pharmaceuticals, Inc. Receptor tyrosine kinase, ar-1, is a regulator of angiogenesis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PEEK R . ET AL: "Molecular cloning of a new angiopoietinlike factor from the human cornea", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 39, no. 10, September 1998 (1998-09-01), pages 1782 - 1788, XP000990829 *
PEEK R. ET AL.: "Molecular cloning of a new angiopoietin-like factor from the human cornea", EMBL DATABASE ; ACCESSION NUMBER Y16132, 1 June 1998 (1998-06-01), XP002136262 *

Also Published As

Publication number Publication date
WO2001029085A2 (en) 2001-04-26
AU1310201A (en) 2001-04-30

Similar Documents

Publication Publication Date Title
WO1997045137A8 (en) Methods and compositions useful for inhibition of angiogenesis
AP1869A (en) b2- Adrenergic receptor agonists.
WO2002076976A3 (en) Rho-kinase inhibitors
IL152754A0 (en) Quinazoline derivatives for the treatment of tumours
WO2000006085A3 (en) Compounds and methods
PT1187918E (en) TEK ANTAGONISTS
WO1999054326A8 (en) Dihydropyrimidines
WO2002057261A3 (en) Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase
CO4910133A1 (en) 5-H ANTAGONISTS [1F]
WO2004080425A3 (en) Polypeptide compounds for inhibiting angiogenesis and tumor growth
WO2000004954A3 (en) Novel urokinase inhibitors
NZ513680A (en) Epitodes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of IgE, antagonists thereof, and their therapeutic uses
HUP0104688A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
WO2000013703A3 (en) Methods of treating hypertension and compositions for use therein
AU2001245295A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
AU2001251613A1 (en) Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
BG105256A (en) Muscarinic agonists and antagonists
AU5497000A (en) Non-malignant disease treatment with ras antagonists
CA2212563A1 (en) Process for obtaining medically active fractions from sea cucumbers
WO2001015677A3 (en) Use of 5-ht1b/1d agonists to treat otic pain
AU2001238493A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
WO2002041831A3 (en) Inositol derivatives for increasing chloride secretion and inhibiting inflammation
CA2416879A1 (en) Methods of treating cancer and the pain associated therewith using endothelin antagonists
WO2001029085A3 (en) Cdt6 can inhibit angiogenesis and tumor growth, and can induce or enhance the formation of structures containing collagen v
AU3896899A (en) Compositions for the treatment of tumors, and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP